COPENHAGEN, Denmark - Genmab A/S (NASDAQ:GMAB), a biotechnology company specializing in pharmaceutical preparations with a market capitalization of $12.2 billion and an impressive 95% gross profit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback